Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.21 is 29% above its 5-year average of -1.70, around the middle of its 5-year range (-2.70–-0.16).
80.60% below its 12-month average of -0.67.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.34.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 28 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.21
EARNINGS PER SHARE (EPS) AVG TTM
-0.67
EARNINGS PER SHARE (EPS) AVG 3Y
-1.32
EARNINGS PER SHARE (EPS) AVG 5Y
-1.70
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-80.60%
CURRENT VS 3Y AVG
+8.33%
CURRENT VS 5Y AVG
+28.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Fulcrum Therapeutics, Inc.
Market Cap
$281.23M
Earnings Per Share (EPS)
-1.21
TTM Avg
-0.67
3Y Avg
-1.32
5Y Avg
-1.70
Market Cap
$280.91M
Earnings Per Share (EPS)
-1.39
TTM Avg
-0.76
3Y Avg
-0.82
5Y Avg
-19.50
Market Cap
$283.18M
Earnings Per Share (EPS)
N/A
TTM Avg
-2880.36
3Y Avg
-1920.24
5Y Avg
-1440.18
Market Cap
$283.11M
Earnings Per Share (EPS)
-6.97
TTM Avg
-33.27
3Y Avg
-41.62
5Y Avg
-70.95
Market Cap
$285.55M
Earnings Per Share (EPS)
-1.11
TTM Avg
-0.10
3Y Avg
-2.07
5Y Avg
-8.75
Market Cap
$285.99M
Earnings Per Share (EPS)
-1.28
TTM Avg
-1.52
3Y Avg
-1.49
5Y Avg
-1.26
Market Cap
$286.75M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.20
3Y Avg
-1.19
5Y Avg
-1.02
Market Cap
$290.87M
Earnings Per Share (EPS)
-1.99
TTM Avg
-1.79
3Y Avg
-1.44
5Y Avg
-2.04
Market Cap
$271.44M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.40
3Y Avg
-1.83
5Y Avg
-1.95
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $281.23M | -1.21 | -0.67 | -1.32 | -1.70 |
| Aurora Cannabis Inc. (ACB)vs › | $280.91M | -1.39 | -0.76 | -0.82 | -19.50 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.18M | N/A | -2880.36 | -1920.24 | -1440.18 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $283.11M | -6.97 | -33.27 | -41.62 | -70.95 |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | -1.11 | -0.10 | -2.07 | -8.75 |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.99M | -1.28 | -1.52 | -1.49 | -1.26 |
| Standard BioTools Inc. (LAB)vs › | $286.75M | -0.23 | -0.20 | -1.19 | -1.02 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.87M | -1.99 | -1.79 | -1.44 | -2.04 |
| Fate Therapeutics, Inc. (FATE)vs › | $271.44M | -1.05 | -1.40 | -1.83 | -1.95 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.25M | -0.17 | -2.37 | -2.73 | -2.69 |
Trailing EPS (TTM)
$-1.21
Forward EPS (Est.)
$-0.60
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.18 |
| 2024-12-31 | -0.16 |
| 2023-12-31 | -1.59 |
| 2022-12-31 | -2.35 |
| 2021-12-31 | -2.22 |
| 2020-12-31 | -2.70 |
| 2019-12-31 | -3.49 |
| 2018-12-31 | -1.92 |
| 2017-12-31 | -1.36 |
